Ligand Pharmaceuticals Inc (NASDAQ:LGND)
| 71.05 Delayed Data As of Jun 05 |  -4.26 / -5.66%Today’s Change | 45.25 Today|||52-Week Range 85.70 | +6.36% Year-to-Date |
Five Year Financial Summary
| All Currency in US Dollars | 4 Quarter Trend | |||||
|---|---|---|---|---|---|---|
| Quarter 3 2018 | Quarter 4 2018 | Quarter 1 2019 | Quarter 2 2019 | |||
| Revenue and Income | Net Revenues | 45.7M | 59.6M | 43.5M | 25.0M | |
| Cost of Goods Sold | 1.5M | 3.0M | 2.3M | 2.2M | ||
| Depreciation And Amortization | 5.7M | 3.5M | 5.1M | 3.7M | ||
| Operating Expenses | Gross Income | 38.5M | 53.2M | 36.1M | 19.1M | |
| General Expenses | 15.1M | 20.0M | 22.4M | 23.2M | ||
| Research And Development | 5.5M | 8.8M | 11.3M | 12.2M | ||
| Total Operating Expenses | 22.3M | 26.4M | 29.7M | 29.1M | ||
| Non-Operating Expenses | Operating Income | 23.4M | 33.1M | 13.7M | -4.1M | |
| Extraordinary Credit | 59.9M | 0.00 | -- | 0.00 | ||
| Extraordinary Charge | -- | -15.0M | -800.0K | 0.00 | ||
| Pre-Tax Equity Earnings | 62.4M | -74.0M | 17.3M | -12.4M | ||
| Interest Expense On Debt | 11.2M | 20.1M | 8.9M | 9.0M | ||
| Other Expenses | -60.7M | 14.3M | 815.5M | -1.8M | ||
| Income Taxes, Minority Interest and Extra Items | Pre-Tax Income | 79.2M | -56.8M | 842.7M | -18.0M | |
| Income Taxes | -11.9M | -14.3M | -176.4M | -3.6M | ||
| Net Income | 67.4M | -42.5M | 666.3M | -14.4M | ||
| Shares To Calculate EPS | Shares To Calculate EPS | 21.1M | 21.1M | 20.4M | 19.6M | |
| Shares To Calculate EPS Diluted | 24.1M | 21.1M | 21.3M | 19.6M | ||
| Earnings Per Share | EPS | $2.80 | -$2.02 | $31.32 | -$0.74 | |
| EPS Diluted | $2.80 | -$2.02 | $31.32 | -$0.74 | ||
